Insmed to Present at September 2026 Investor Conferences
Rhea-AI Summary
Insmed (Nasdaq: INSM) announced that management will present at two September 2026 investor conferences in New York City: the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9 at 8:00 a.m. ET and the 24th Annual Morgan Stanley Global Healthcare Conference on September 14 at 2:35 p.m. ET. Live webcasts and 30-day archives will be available via Insmed's investor relations website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 24 | Japan regulatory approval | Positive | -1.4% | Japan authorization expanded BRINSUPRI access for non-cystic fibrosis bronchiectasis patients. |
| Aug 06 | Second-quarter earnings | Positive | +33.9% | Q2 revenue growth and raised BRINSUPRI guidance drove the positive response. |
| Jul 23 | Earnings call scheduling | Neutral | +0.7% | Scheduled Q2 results call and business update preceded a positive response. |
| Jul 16 | TPIP clinical data | Positive | -2.1% | Positive 12-month TPIP extension data preceded a negative stock response. |
| Jun 23 | Leadership appointment | Positive | +3.6% | New global respiratory general manager appointment preceded a positive response. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock showed mixed historical responses, with two positive announcements followed by declines and three events followed by gains.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- 12th Annual Cantor Fitzgerald Global Healthcare Conference in
New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET. - 24th Annual Morgan Stanley Global Healthcare Conference in
New York City on Monday, September 14, 2026, at 2:35 p.m. ET.
These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.
Contact:
Investors:
Sara Bonstein
Chief Financial Officer
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-september-2026-investor-conferences-302860496.html
SOURCE Insmed Incorporated